Search filters
 Trial Filters
Clear All
  • 5
  • 4
  • 1
  • 5

Phase

  • 2
  • 1
  • 2

Solid Tumor Clinical Trials

A listing of Solid Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 5 clinical trials
Tusamitamab Ravtansine in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01)

Primary Objective: -To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and metastatic pancreatic adenocarcinoma (mPAC) Secondary Objective: To assess the safety and tolerability of tusamitamab ravtansine To assess other efficacy parameters of tusamitamab ravtansine To assess the immunogenicity of tusamitamab ravtansine

Phase 2
Learn more
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

Primary Objectives: Part 1 (Dose Escalation) To determine the MTD/maximum administered dose (MAD) of SAR443216 administered as a single agent in participants with HER2 expressing solid tumors and determine the RP2D in the dose escalation part. To determine the maximum lead-in dose and the recommended target dose for phase 2. …

Phase 1
Learn more
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Primary Objectives: Dose Escalation: To determine maximum tolerated dose (MTD) or maximum administered dose (MAD) and overall safety and tolerability profile of SAR441000 when administered intratumorally as monotherapy and in combination with cemiplimab in patients who have no alternative standard treatment options. Dose Expansion (Combination): To determine the objective response …

Phase 1
Learn more
Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies

Primary Objectives: Part 1 To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in participants with advanced solid tumors. To define the MTD and RP2D for the combination of SAR442720 and pembrolizumab in participants with solid tumors. Part 2 To determine the anti-tumor activity of SAR442720 in …

Phase 1/2
Learn more
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

Primary Objectives: Evaluate the safety and tolerability of THOR-707 as a single agent and as a combination therapy (identify Dose Limiting Toxcitiy (DLTs), Adverse Events (AEs)/serious adverse event (SAE) profile) Define the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of THOR-707 as a single agent and …

Phase 1/2
Learn more